Kinoshita Y, et al. - Efficacy and safety of twice daily (BID) rabeprazole maintenance therapy for patients with reflux esophagitis (RE) refractory to standard once daily (QD) proton pump inhibitor (PPI) were investigated in this study. Rabeprazole at 10 mg BID exerted a stronger recurrence-preventing effect than 10 mg QD over 52 weeks in the maintenance treatment of PPI-resistant RE. During long-term administration, no particular safety issues were noted.